Chronic Rhinosinusitis: Making Treatment Decisions
Price: FREE for members and non-members
Session recorded on December 10, 2020
Speaker: Wesley Sublett, MD
Viewers can earn credit by completing the posttest questions
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
There is no commercial support for this activity.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Primary Care Providers
Fellows-in-Training
Learning Objectives
Upon completion of this activity learners should be able to:
- Define chronic rhinosinusitis
- Discuss the evaluation tools utilized in CRS
- Evaluate medical treatments of CRS
- Evaluate surgical treatments of CRS
All identified conflicts of interest have been resolved.
Sally Schlosser, RN, Planner, Reviewer
Nothing to disclose
Michael Blaiss, MD, Planner
Disclosures: Consultant/Consulting fee: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
Wesley Sublett, MD, Speaker
Disclosures: Speaker/Honorarium/Clinical Investigator/Contracted Research: Astra Zeneca, DBV Technologies, Pfizer, Aimmune, ALK, Novartis, Regeneron, Optinose
Consultant/Consulting fees: Kaleo
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance